Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Vaccines

Free Subscription 27.06.2022 1 AIDS 1 Arch Virol 5 BMJ 11 Clin Infect Dis 1 Infect Immun 1 J Immunol 1 J Infect 6 J Infect Dis 1 J Pediatr 1 J Virol 2 JAMA 1 MMWR Morb Mortal Wkly Rep 9 N Engl J Med 2 Nat Med 3 Pediatrics 3 PLoS Med 9 PLoS One 1 Proc Natl Acad Sci U S A 26 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AIDS

1. POURCHER V, Belin L, Soulie C, Rosenzwajg M, et al
   High seroconversion rate and SARS-CoV-2 Delta neutralization in PLWHIV vaccinated with BNT162b2.
   AIDS. 2022 Jun 23. pii: 00002030-990000000-00043.
   PubMed         Abstract available
   
   

   
   Arch Virol

2. DAHER-NASHIF S, Al-Anany R, Ali M, Erradi K, et al
   COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity.
   Arch Virol. 2022 Jun 20. pii: 10.1007/s00705-022-05495.
   PubMed         Abstract available
   
   

   
   BMJ

3. WISE J
   Covid-19: UK makes first payments to compensate injury or death from vaccines.
   BMJ. 2022;377:o1565.
   PubMed        
   
   
4. WISE J
   Moderna to open mRNA vaccine research and manufacturing centre in the UK.
   BMJ. 2022;377:o1556.
   PubMed        
   
   
5. MAHASE E
   Monkeypox: Gay and bisexual men with high exposure risk will be offered vaccine in England.
   BMJ. 2022;377:o1542.
   PubMed        
   
   
6. LI X, Ostropolets A, Makadia R, Shoaibi A, et al
   Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.
   BMJ. 2021;373:n1435.
   PubMed         Abstract available
   
   
7. TANNE JH
   Covid-19: CDC and FDA approve Pfizer and Moderna vaccines for under 5s.
   BMJ. 2022;377:o1507.
   PubMed        
   
   

   
   Clin Infect Dis

8. ROTTENSTREICH A, Zarbiv G, Oiknine-Djian E, Vorontsov O, et al
   Kinetics of maternally-derived anti- SARS-CoV-2 antibodies in infants in relation to the timing of antenatal vaccination.
   Clin Infect Dis. 2022 Jun 19. pii: 6611486. doi: 10.1093.
   PubMed         Abstract available
   
   
9. RICHARDSON VL, Franco MAC, Marquez AB, Valdez LM, et al
   Vaccine effectiveness of CanSino (Adv5-nCoV) COVID-19 vaccine among childcare workers - Mexico, March-December 2021.
   Clin Infect Dis. 2022 Jun 19. pii: 6611492. doi: 10.1093.
   PubMed         Abstract available
   
   
10. VU DM, Vu DTB, Do TTT, Olmsted AE, et al
    Presence of SARS-CoV-2 Antibodies among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine.
    Clin Infect Dis. 2022 Jun 20. pii: 6611567. doi: 10.1093.
    PubMed         Abstract available
    
    
11. ROSKOSKY M, Moni G, Kawakami V, Lambert J, et al
    SARS-CoV-2 Transmission Associated with an Indoor Music Event That Required Proof of Full Vaccination Against COVID-19 Prior to Entry-Seattle, July 2021.
    Clin Infect Dis. 2022 Jun 20. pii: 6611550. doi: 10.1093.
    PubMed         Abstract available
    
    
12. BROSH-NISSIMOV T, Hussein K, Wiener-Well Y, Orenbuch-Harroch E, et al
    Hospitalized patients with severe COVID-19 during the Omicron wave in Israel - benefits of a fourth vaccine dose.
    Clin Infect Dis. 2022 Jun 20. pii: 6611845. doi: 10.1093.
    PubMed         Abstract available
    
    
13. OHLSEN EC, Yankey D, Pezzi C, Kriss JL, et al
    COVID-19 vaccination coverage, intentions, attitudes and barriers by race/ethnicity, language of interview, and nativity, National Immunization Survey Adult COVID Module, April 22, 2021-January 29, 2022.
    Clin Infect Dis. 2022 Jun 23. pii: 6614630. doi: 10.1093.
    PubMed         Abstract available
    
    
14. MORROCCHI E, Pighi C, Pascucci GR, Cotugno N, et al
    Perinatally HIV-infected adolescents and young adults demonstrate distinct BNT162b2 mRNA COVID-19 vaccine immunogenicity.
    Clin Infect Dis. 2022 Jun 23. pii: 6615389. doi: 10.1093.
    PubMed         Abstract available
    
    
15. PLOTKIN SA
    Why We Need Precision Vaccinology.
    Clin Infect Dis. 2022 Jun 23. pii: 6615391. doi: 10.1093.
    PubMed        
    
    
16. CHOI D, Nielsen J, Waller LA, Patel SA, et al
    The US COVID-19 surveillance environment: An ecological analysis of the relationship of testing adequacy in the context of vaccination.
    Clin Infect Dis. 2022 Jun 24. pii: 6617111. doi: 10.1093.
    PubMed         Abstract available
    
    
17. KUTTY PK, Stuckey MJ, Koumans EH
    Vaccines, Variants, and Vigilance: Strengthening the COVID-19 Public Health Response through Partnerships and Collaborations.
    Clin Infect Dis. 2022 Jun 24. pii: 6617337. doi: 10.1093.
    PubMed         Abstract available
    
    
18. OH DY, Holzer M, Paraskevopoulou S, Trofimova M, et al
    Advancing Precision Vaccinology by Molecular and Genomic Surveillance of SARS-CoV-2 in Germany, 2021.
    Clin Infect Dis. 2022 Jun 25. pii: 6617635. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Infect Immun

19. DAYAO DA, Jaskiewcz J, Lee S, Oliveira BC, et al
    Development of Two Mouse Models for Vaccine Evaluation against Cryptosporidiosis.
    Infect Immun. 2022 Jun 23:e0012722. doi: 10.1128/iai.00127.
    PubMed         Abstract available
    
    

    
    J Immunol

20. CUSIMANO GM, Gary EN, Bell MR, Warner BM, et al
    Improved Durability to SARS-CoV-2 Vaccine Immunity following Coimmunization with Molecular Adjuvant Adenosine Deaminase-1.
    J Immunol. 2022 Jun 24. pii: jimmunol.2200056. doi: 10.4049/jimmunol.2200056.
    PubMed         Abstract available
    
    

    
    J Infect

21. LAZARUS R, Taucher C, Brown C, Corbic I, et al
    Safety and immunogenicity of the inactivated whole-virus adjuvanted vaccine VLA2001: a randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.
    J Infect. 2022 Jun 16. pii: S0163-4453(22)00361.
    PubMed         Abstract available
    
    

    
    J Infect Dis

22. DONATO CM, Roczo-Farkas S, Kirkwood CD, Barnes GL, et al
    Rotavirus Disease and Genotype Diversity in Older Children and Adults in Australia.
    J Infect Dis. 2022;225:2116-2126.
    PubMed         Abstract available
    
    
23. LEMASTER C, Geanes ES, Fraley ER, Selvarangan R, et al
    Vaccination after SARS-CoV-2 infection increased antibody avidity against the Omicron variant compared to vaccination alone.
    J Infect Dis. 2022 Jun 18. pii: 6609994. doi: 10.1093.
    PubMed         Abstract available
    
    
24. GUIRAKHOO F, Wang S, Wang CY, Kuo HK, et al
    High neutralizing antibody levels against SARS-CoV-2 Omicron BA.1 and BA.2 after UB-612 vaccine booster.
    J Infect Dis. 2022 Jun 20. pii: 6611838. doi: 10.1093.
    PubMed         Abstract available
    
    
25. VARESE A, Mazzitelli B, Diaz FE, Kjolhede MV, et al
    Omicron breakthrough infection after heterologous prime-boost vaccination induces a vigorous antibody response.
    J Infect Dis. 2022 Jun 20. pii: 6611839. doi: 10.1093.
    PubMed         Abstract available
    
    
26. CUNNINGHAM CK, Karron RA, Muresan P, Kelly MS, et al
    Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/DeltaNS2/Delta1313/I1314L and RSV/276 in RSV Seronegative Children.
    J Infect Dis. 2022 Jun 23. pii: 6613410. doi: 10.1093.
    PubMed         Abstract available
    
    
27. STRENG BMM, Bont M, Delemarre EM, Binnendijk RS, et al
    Decreased antibody response after SARS-CoV-2 vaccination in patients with Down Syndrome.
    J Infect Dis. 2022 Jun 24. pii: 6617441. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Pediatr

28. CASKEY R
    HPV vaccination associated with decreased cervical cancer incidence and mortality.
    J Pediatr. 2022;245:246-249.
    PubMed        
    
    

    
    J Virol

29. KIM A, Lee G, Hwang JH, Park JH, et al
    BacMam Expressing Highly Glycosylated Porcine Interferon Alpha Induces Robust Antiviral and Adjuvant Effects against Foot-and-Mouth Disease Virus in Pigs.
    J Virol. 2022;96:e0052822.
    PubMed         Abstract available
    
    

    
    JAMA

30. ABBASI J
    COVID-19 mRNA Vaccine Booster During Pregnancy Increases Maternal and Fetal Antibodies.
    JAMA. 2022 Jun 22. pii: 2793740. doi: 10.1001/jama.2022.11145.
    PubMed        
    
    
31. LARKIN HD
    mRNA COVID-19 Vaccine Booster After Inactivated Vaccine Primary Series.
    JAMA. 2022;327:2280.
    PubMed        
    
    

    
    MMWR Morb Mortal Wkly Rep

32. MARTIN J, Burns CC, Jorba J, Shulman LM, et al
    Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021.
    MMWR Morb Mortal Wkly Rep. 2022;71:786-790.
    PubMed         Abstract available
    
    

    
    N Engl J Med

33. ZENG G
    BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
    N Engl J Med. 2022;386:2345-2346.
    PubMed        
    
    
34. PRICE AM, Olson SM, Patel MM
    BNT162b2 Protection against the Omicron Variant in Children and Adolescents. Reply.
    N Engl J Med. 2022;386:2346.
    PubMed        
    
    
35. WOHL A, Leibowitz R
    Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
    N Engl J Med. 2022;386:2441.
    PubMed        
    
    
36. BAR-ON YM, Goldberg Y, Milo R
    Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. Reply.
    N Engl J Med. 2022;386:2441-2442.
    PubMed        
    
    
37. SCHMOELE-THOMA B, Zareba AM, Jiang Q, Maddur MS, et al
    Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
    N Engl J Med. 2022;386:2377-2386.
    PubMed         Abstract available
    
    
38. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Vaccinating Young Children against Covid-19.
    N Engl J Med. 2022;386:e77.
    PubMed        
    
    
39. RASMUSSEN SA, Jamieson DJ
    Covid-19 Vaccination during Pregnancy - Two for the Price of One.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMe2206730.
    PubMed        
    
    
40. HALASA NB, Olson SM, Staat MA, Newhams MM, et al
    Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMoa2204399.
    PubMed         Abstract available
    
    
41. DESILVA M, Haapala J, Vazquez-Benitez G, Vesco KK, et al
    Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMc2205276.
    PubMed        
    
    

    
    Nat Med

42. CAO L, Lou J, Chan SY, Zheng H, et al
    Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01877.
    PubMed         Abstract available
    
    
43. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    A randomized controlled trial to test financial incentives for COVID-19 vaccination in Ghana.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01876.
    PubMed        
    
    

    
    Pediatrics

44. LU PJ, Yankey D, Fredua B, Hung MC, et al
    Human Papillomavirus Vaccination Trends Among Adolescents: 2015 to 2020.
    Pediatrics. 2022 Jun 22. pii: 188308. doi: 10.1542/peds.2022-056597.
    PubMed         Abstract available
    
    
45. INFECTIOUS DISEASES CO
    COVID-19 Vaccines in Infants, Children, and Adolescents.
    Pediatrics. 2022 Jun 18. pii: 188297. doi: 10.1542/peds.2022-058700.
    PubMed         Abstract available
    
    
46. BUCHAN SA, Nguyen L, Wilson SE, Kitchen SA, et al
    Vaccine Effectiveness of BNT162b2 Against Delta and Omicron Variants in Adolescents.
    Pediatrics. 2022 Jun 16. pii: 188277. doi: 10.1542/peds.2022-057634.
    PubMed         Abstract available
    
    

    
    PLoS Med

47. TAKUVA S, Takalani A, Seocharan I, Yende-Zuma N, et al
    Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
    PLoS Med. 2022;19:e1004024.
    PubMed         Abstract available
    
    
48. WONG CKH, Lau KTK, Xiong X, Au ICH, et al
    Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    PLoS Med. 2022;19:e1004018.
    PubMed         Abstract available
    
    
49. QIAN G, Toizumi M, Clifford S, Le LT, et al
    Association of pneumococcal carriage in infants with the risk of carriage among their contacts in Nha Trang, Vietnam: A nested cross-sectional survey.
    PLoS Med. 2022;19:e1004016.
    PubMed         Abstract available
    
    

    
    PLoS One

50. TAKEUCHI M, Esaki A, Higa Y, Nakazono A, et al
    Temporal changes in spike IgG levels after two doses of BNT162b2 vaccine in Japanese healthcare workers: Do spike IgG levels at 3 months predict levels 6 or 8 months after vaccination?
    PLoS One. 2022;17:e0263486.
    PubMed         Abstract available
    
    
51. BACURAU AGM, Sato APS, Francisco PMSB
    Correction: Reasons for nonadherence to vaccination for influenza among older people in Brazil.
    PLoS One. 2022;17:e0270443.
    PubMed         Abstract available
    
    
52. LANIER HD, Diaz MI, Saleh SN, Lehmann CU, et al
    Analyzing COVID-19 disinformation on Twitter using the hashtags #scamdemic and #plandemic: Retrospective study.
    PLoS One. 2022;17:e0268409.
    PubMed         Abstract available
    
    
53. MOONEY J, Price J, Bain C, Bawa JT, et al
    Healthcare provider perspectives on delivering next generation rotavirus vaccines in five low-to-middle-income countries.
    PLoS One. 2022;17:e0270369.
    PubMed         Abstract available
    
    
54. SIEWCHAISAKUL P, Sarakarn P, Nanthanangkul S, Longkul J, et al
    Role of literacy, fear and hesitancy on acceptance of COVID-19 vaccine among village health volunteers in Thailand.
    PLoS One. 2022;17:e0270023.
    PubMed         Abstract available
    
    
55. CERVANTES-LUEVANO K, Espino-Vazquez AN, Flores-Acosta G, Bernaldez-Sarabia J, et al
    Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico.
    PLoS One. 2022;17:e0269032.
    PubMed         Abstract available
    
    
56. DESALEGN M, Garoma G, Tamrat H, Desta A, et al
    The prevalence of AstraZeneca COVID-19 vaccine side effects among Nigist Eleni Mohammed memorial comprehensive specialized hospital health workers. Cross sectional survey.
    PLoS One. 2022;17:e0265140.
    PubMed         Abstract available
    
    
57. ACHENBACH CJ, Caputo M, Hawkins C, Balmert LC, et al
    Clinical evaluation of the Diagnostic Analyzer for Selective Hybridization (DASH): A point-of-care PCR test for rapid detection of SARS-CoV-2 infection.
    PLoS One. 2022;17:e0270060.
    PubMed         Abstract available
    
    
58. ABAY ES, Belew MD, Ketsela BS, Mengistu EE, et al
    Assessment of attitude towards COVID-19 vaccine and associated factors among clinical practitioners in Ethiopia: A cross-sectional study.
    PLoS One. 2022;17:e0269923.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

59. SIEWERT LK, Korotaev A, Sedzicki J, Fromm K, et al
    Identification of the Bartonella autotransporter CFA as a protective antigen and hypervariable target of neutralizing antibodies in mice.
    Proc Natl Acad Sci U S A. 2022;119:e2202059119.
    PubMed         Abstract available
    
    

    
    Vaccine

60. ULANOVA M, Huska B, Dubois S, McCready W, et al
    Opsonophagocytic activity against Streptococcus pneumoniae in Indigenous and non-Indigenous patients with severe chronic kidney disease immunized with 13-valent pneumococcal conjugate vaccine.
    Vaccine. 2022 Jun 20. pii: S0264-410X(22)00810.
    PubMed         Abstract available
    
    
61. LIN K, Liu M, Bao L, Lv Q, et al
    Safety and protective capability of an inactivated SARS-CoV-2 vaccine on pregnancy, lactation and the growth of offspring in hACE2 mice.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00765.
    PubMed         Abstract available
    
    
62. DIONATO FAV, Jalalizadeh M, Buosi K, Visacri MB, et al
    BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial.
    Vaccine. 2022 Jun 20. pii: S0264-410X(22)00803.
    PubMed         Abstract available
    
    
63. KASAIJA PD, Contreras M, Kabi F, Mugerwa S, et al
    Oral vaccine formulation combining tick Subolesin with heat inactivated mycobacteria provides control of cross-species cattle tick infestations.
    Vaccine. 2022 Jun 18. pii: S0264-410X(22)00804.
    PubMed         Abstract available
    
    
64. CASAGRANDE TZ, Costa-Rocha IAD, Gavi MBRO, Miyamoto ST, et al
    Previous biological therapy and impairment of the IFN-gamma/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis.
    Vaccine. 2022 Jun 18. pii: S0264-410X(22)00703.
    PubMed         Abstract available
    
    
65. GAMBRELL A, Sundaram M, Bednarczyk RA
    Estimating the number of US children susceptible to measles resulting from COVID-19-related vaccination coverage declines.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00782.
    PubMed         Abstract available
    
    
66. FOLEGATTI PM, Jenkin D, Morris S, Gilbert S, et al
    Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00755.
    PubMed         Abstract available
    
    
67. HERNANDEZ LM, Sumathy K, Sahastrabuddhe S, Excler JL, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00753.
    PubMed         Abstract available
    
    
68. WALKER JL, Schultze A, Tazare J, Tamborska A, et al
    Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00757.
    PubMed         Abstract available
    
    
69. WYNBERG E, Han AX, Boyd A, van Willigen HDG, et al
    The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00748.
    PubMed         Abstract available
    
    
70. RAZZAGHI H, Yankey D, Vashist K, Lu PJ, et al
    COVID-19 vaccination coverage and intent among women aged 18-49 years by pregnancy status, United States, April-November 2021.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00779.
    PubMed         Abstract available
    
    
71. MOSS P, Berenbaum F, Curigliano G, Grupper A, et al
    Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00682.
    PubMed         Abstract available
    
    
72. UWAMINO Y, Kurafuji T, Takato K, Sakai A, et al
    Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00763.
    PubMed         Abstract available
    
    
73. NOWALK MP, D'Agostino H, Dauer K, Stiegler M, et al
    Estimating the burden of adult hospitalized RSV infection including special populations.
    Vaccine. 2022;40:4121-4127.
    PubMed         Abstract available
    
    
74. KUNASEKARAN MP, Chughtai AA, Heslop DJ, Poulos CJ, et al
    Influenza cases in nine aged care facilities in Sydney, Australia over a three-year surveillance period, 2018-2020.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00476.
    PubMed         Abstract available
    
    
75. CHUNG JR, Kim SS, Flannery B, Smith ME, et al
    Vaccine-associated attenuation of subjective severity among outpatients with influenza.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00767.
    PubMed         Abstract available
    
    
76. HALSTEAD IN, McKay RT, Lewis GJ
    COVID-19 and seasonal flu vaccination hesitancy: Links to personality and general intelligence in a large, UK cohort.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00678.
    PubMed         Abstract available
    
    
77. ZHANG H, Li Y, Peng S, Jiang Y, et al
    The effect of health literacy on COVID-19 vaccine hesitancy among community population in China: The moderating role of stress.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00762.
    PubMed         Abstract available
    
    
78. CIMOLAI N
    Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3985-3986.
    PubMed        
    
    
79. MOGHNIEH R, Abdallah D, Sayegh MH, Rahman Bizri A, et al
    Response to letter to the editor: Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3987-3988.
    PubMed        
    
    
80. ARAUJO BC, Simakawa R, Munhoz LG, Carmo FB, et al
    Rubella antibodies in vertically and horizontally HIV-infected young adults vaccinated early in life and response to a booster dose in those with seronegative results.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00774.
    PubMed         Abstract available
    
    
81. BRAUNFELD JB, Carson HN, Williams SR, Schwartz LM, et al
    Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00778.
    PubMed         Abstract available
    
    
82. TSENG HF, Sy LS, Ackerson BK, Lee GS, et al
    Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00756.
    PubMed         Abstract available
    
    
83. TAY S, Bowen AC, Blyth CC, Clifford P, et al
    A quality improvement study: Optimizing pneumococcal vaccination rates in children with cochlear implants.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00769.
    PubMed         Abstract available
    
    
84. CANADAY LM, Resnick JD, Liu H, Powell H, et al
    HA and M2 sequences alter the replication of 2013-16 H1 live attenuated influenza vaccine infection in human nasal epithelial cell cultures.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00733.
    PubMed         Abstract available
    
    
85. PHATARPHEKAR A, Vidyadhar Reddy GEC, Gokhale A, Karanam G, et al
    RelCoVax(R), a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00775.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: